AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00810303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose
Description: administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)
Study NCT00810303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustiva (efavirenz) single dose
Description: administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
Study NCT06132321 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Detecting by mean of questionnaires quality of life, urinary function, pain, sexual function and lymphedema status before and after surgery for vulvar cancer, associated or not to vulvar reconstruction
Study NCT03381430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg/day oral daily
Study NCT03583437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
Study NCT01094171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix TM
Description: Intramuscular administration, 3 doses
Study NCT01094171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix TM
Description: Intramuscular administration, 3 doses
Study NCT03301922 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Metacognitive therapy and work-focused interventions
Description: Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
Study NCT03301922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy and work-focused interventions
Description: Metacognitive therapy and work-focused interventions, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
Study NCT03301922 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list
Description: Waiting list
Study NCT01495507 — intervention group
Intervention type: PROCEDURE
Intervention: MPFL- Reconstruction
Study NCT03872583 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control website
Description: Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
Study NCT03743012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated cardiac rehabilitation
Description: Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
Study NCT03743012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
Study NCT03180190 — intervention group
Intervention type: DRUG
Intervention: Hydroxychloroquine Oral Tablet
Description: slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~* Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~* Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)
Study NCT04077684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
Study NCT01322334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing exercises
Description: A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
Study NCT00776867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
Study NCT01465061 — intervention group
Intervention type: BEHAVIORAL
Intervention: Online support group
Description: Joining online support group
Study NCT01087242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tang-min Lin pill
Description: Tang-min Lin pill 6g,tid,treat 12 weeks.
Study NCT01087242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tang-min Lin pill
Description: Tang-min Lin pill 6g,tid,treat 12 weeks.
Study NCT00715000 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral rehydration therapy
Description: oral rehydration solution
Study NCT00715000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical hydration via intravenous infusion
Description: intravenous infusion
Study NCT02685514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU Graves
Description: The HIFU treatment technique will be applied to the recruited participants
Study NCT03881410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: different types of ultrasound technique
Description: Shear-wave elastography-guided or Convention ultrasound-guided
Study NCT03881410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different types of ultrasound technique
Description: Shear-wave elastography-guided or Convention ultrasound-guided
Study NCT03703050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab cohort 1
Description: Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
Study NCT04077684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interleukin-2
Description: IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
Study NCT03956173 — intervention group
Intervention type: OTHER
Intervention: Hypoglycemic combined with either normo or hyperglycemic clamp.
Description: Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperglyemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
Study NCT03703050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab cohort 2
Description: Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
Study NCT01453660 — intervention group
Intervention type: OTHER
Intervention: Endo-PAT2000 testing
Description: Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
Study NCT01453660 — intervention group
Intervention type: OTHER
Intervention: Endo-PAT2000 testing
Description: Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, \& urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure \& heart rate, including orthostatics \& Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, \& urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
Study NCT05179824 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: No Intervention
Study NCT05349084 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET-cCTA-cFFR
Description: patients presenting with stable angina and a moderate pretest likelihood for CAD who are already scheduled to undergo ICA for the clinical indication of angina will be recruited to undergo PET-cCTA-cFFR
Study NCT02243007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Study NCT02243007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/nab-Paclitaxel
Study NCT02243007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT02243007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT01991717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Victus
Description: The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
Study NCT01991717 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional Phaco
Description: The capsulotomy as well as the lens fragmentation is performed manually.
Study NCT03670381 — intervention group
Intervention type: OTHER
Intervention: Psychiatric diagnosis
Study NCT01068054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: 0.1% ointment,apply bid, 8 weeks
Study NCT01068054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporins
Description: 2% eyclosporine eye drops apply 1 drop to each eye QID
Study NCT02336893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
Study NCT00104611 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Study NCT00104611 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Study NCT00438971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
Study NCT03040193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine Nebulization
Description: 4% Lignocaine delivered via Nebulization
Study NCT03040193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nebulization
Description: Normal Saline Delivered via Nebulization
Study NCT02553941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given intravenous or subcutaneous
Study NCT02553941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given by mouth once daily
Study NCT00657774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FlutiForm 250/10 ug
Description: SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
Study NCT00657774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FlutiForm 100/10 ug
Description: SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
Study NCT00657774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Prednisone 10mg
Description: 2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
Study NCT00657774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
Study NCT03436563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PD-L1/TGFbetaRII Fusion Protein M7824
Description: Given IV
Study NCT04133038 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
Study NCT02151409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
Study NCT02151409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0151-0000-0000
Description: A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
Study NCT02151409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
Study NCT02345642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiveCare+SFT Supine
Study NCT02345642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveCare+SFT Supine
Study NCT02345642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VenaFlow Elite Supine
Study NCT02345642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaFlow Elite Supine
Study NCT02345642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiveCare+SFT Standing
Study NCT02345642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiveCare+SFT Standing
Study NCT02345642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VenaFlow Elite Standing
Study NCT04845373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Diet intervention:Mediterranean diet
Study NCT04845373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet: Low fat diet
Description: Low fat diet
Study NCT03844607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
Study NCT03844607 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation (tDCS)
Description: Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
Study NCT03673930 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zanthozylum armatum
Description: Zanthozylum armatum MCT oil extract
Study NCT03673930 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sunflower oil matched for appearance
Study NCT04540575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NICU Acquires MOM
Description: Mother receives 1) hospital-grade electric smart breast pump for home use at no charge to the mother while the infant is in the NICU and the mother continues to pump; 2) free pickup of expressed MOM from home to transport to NICU 2-3 times per week during weekdays as needed; 3) receives payment for opportunity costs of pumping and handling milk at $24.00/day for each day that the mother pumps during her infant's NICU stay
Study NCT04540575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother Provides MOM
Description: Mother receives standard Rush NICU lactation care
Study NCT04540575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Provides MOM
Description: Mother receives standard Rush NICU lactation care
Study NCT00378105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
Study NCT00378105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
Study NCT00378105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
Study NCT04735536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT1812
Description: Active Treatment- CT1812 at a dose of 300mg
Study NCT04735536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CT1812
Description: Active Treatment- CT1812 at a dose of 300mg
Study NCT04735536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator
Study NCT04735536 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT01910571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P7435
Study NCT01910571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00423670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir (SCH 503034)
Description: 200 mg capsules taken as 800 mg orally three times daily (TID)
Study NCT02345642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaFlow Elite Standing
Study NCT00423670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon-alfa 2b (PegIntron)
Description: 1.5 μg/kg subcutaneously (SC) once weekly (QW)
Study NCT03670082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: 20 mg Lu AF35700 single oral dose
Study NCT03670082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700 iv
Description: 100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
Study NCT00568789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon, zolpidem and placebo
Description: Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3
Study NCT05165576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child-centered communication
Description: The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
Study NCT05165576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-centered communication
Description: The child is asked for ideas, fears and concerns regarding the magnetic resonance imaging exam and responses are tailored to these individual needs
Study NCT02008929 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MG4101
Description: Ex vivo expanded allogeneic NK cell
Study NCT02094586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 Lot A
Description: Lot P700-1CA03
Study NCT02094586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 Lot B
Description: Lot P700-3CA03
Study NCT02094586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 Lot C
Description: Lot P700-6BA03
Study NCT02094586 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo